| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
Purity: ≥98%
Triflusal (formerly UR1501; Disgren, Grendis, Aflen, Triflux), a platelet aggregation inhibitor and a salicylate analog, acts by irreversibly inhibiting the production of thromboxane-B2 in platelets via acetylating the enzyme COX-1/cycloxygenase-1. The main metabolite of Triflusal is HTB, which preserves 6-keto-PGF1α synthesis in porcine aortic endothelial cells (PAEC) cells without a significant decline for up to 24 h even at the higher concentration. Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively. Triflusal also reduces inducible NO synthase activity by 18%, 21% and 30%.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Trifluralin is absorbed in the small intestine with a bioavailability of 83% to 100%. There is no significant difference in absorption between oral solutions and capsules. The peak plasma concentration (Cmax) of trifluralin is 11.6 mcg/ml, and the time to peak concentration (tmax) is 0.88 hours. The major metabolite of trifluralin exhibits different pharmacokinetic characteristics, with a Cmax of 92.7 mcg/ml and a time to peak concentration (tmax) of 4.96 hours, respectively. Trifluralin is primarily excreted via the kidneys. Urinary analysis shows the presence of unmetabolized trifluralin, HTB, and its glycine conjugates. The reported volume of distribution of trifluralin is 34 liters. The renal clearances of trifluralin and HTB are 0.8 ± 0.2 L/h and 0.18 ± 0.04 L/h, respectively. Metabolism/Metabolites In the liver, trifluorosalicylate undergoes deacetylation to produce its major metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB). This major metabolite appears to have significant antiplatelet activity in vitro. Biological Half-Life In healthy humans, the half-life of trifluorosalicylate is 0.5 ± 0.1 hours, while the half-life of HTB is 34.3 ± 5.3 hours. Biological Half-Life In healthy humans, the half-life of trifluorosalicylate is 0.5 ± 0.1 hours, while the half-life of HTB is 34.3 ± 5.3 hours. |
||
| Toxicity/Toxicokinetics |
Protein Binding
Trifluralin binds almost completely to plasma proteins, achieving 99% of the administered dose. |
||
| References |
J Thromb Haemost.2008 Aug;6(8):1385-92;Eur J Clin Invest.2000 Sep;30(9):811-7.
|
||
| Additional Infomation |
2-Acetoxy-4-(trifluoromethyl)benzoic acid belongs to the salicylates, carboxylates, and benzoic acids. Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid molecule with a chemical structure similar to aspirin, but it is not a derivative of aspirin. Its advantage lies in that it does not affect the arachidonic acid pathway, promotes nitric oxide production, and increases the concentration of cyclic nucleotides on endothelial cells. The latter promotes peripheral vasodilation. Due to its low bleeding risk, triflusal is important in the secondary prevention of ischemic stroke. Developed by J. Uriach, it is marketed in several countries but has not yet been approved by the US FDA, EMA, or Health Canada. Indications: Triflusal is indicated for the prevention of thromboembolic diseases. It is registered in Spain and other countries in Europe, South America, and South Korea for the prevention of stroke and myocardial infarction. Mechanism of Action Trifluralin is chemically related to acetylsalicylic acid (ASA) and irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets. Acetylation of the active group of COX-1 prevents the formation of thromboxane B2 in platelets. However, it is unique in that it does not affect the arachidonic acid metabolic pathway in endothelial cells. Furthermore, it promotes the production of the vasodilator nitric oxide. Pharmacodynamics Trifluralin is an antithrombotic and anticoagulant. It irreversibly inhibits the formation of thromboxane B2 in platelets by acetylation of cyclooxygenase-1. Trifluralin also affects many other targets, such as NF-κB, a regulator of gene expression of cyclooxygenase-α and cytokines. Numerous studies comparing the efficacy and safety (e.g., systemic bleeding) of trifluralin and acetylsalicylic acid have shown no significant difference in efficacy and safety, or that trifluralin may have better efficacy and safety. Studies have shown that trifluralin can inhibit lipid peroxidation during hypoxia-reoxygenation, thereby protecting brain tissue.
|
| Molecular Formula |
C10H7F3O4
|
|
|---|---|---|
| Molecular Weight |
248.16
|
|
| Exact Mass |
248.029
|
|
| CAS # |
322-79-2
|
|
| Related CAS # |
Triflusal-d3;2748541-63-9
|
|
| PubChem CID |
9458
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
316.0±42.0 °C at 760 mmHg
|
|
| Melting Point |
115 °C
|
|
| Flash Point |
144.9±27.9 °C
|
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
|
| Index of Refraction |
1.484
|
|
| LogP |
2.9
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
17
|
|
| Complexity |
313
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
RMWVZGDJPAKBDE-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
|
|
| Chemical Name |
2-acetyloxy-4-(trifluoromethyl)benzoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (12.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (12.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (12.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0297 mL | 20.1483 mL | 40.2966 mL | |
| 5 mM | 0.8059 mL | 4.0297 mL | 8.0593 mL | |
| 10 mM | 0.4030 mL | 2.0148 mL | 4.0297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02904109 | Completed | Drug: Triflusal Drug: Placebo |
Healthy | Prof. Dominique de Quervain, MD | September 13, 2016 | Phase 2 |
| NCT02321852 | Completed | Drug: Triflusal Drug: Placebo |
Healthy | Prof. Dominique de Quervain, MD | January 2015 | Phase 2 |
| NCT01612273 | Completed | Drug: Triflusal Drug: Aspirin |
Vasospastic Syndrome | Yonsei University | April 2011 | Phase 4 |
| NCT01174693 | Completed | Drug: Triflusal Drug: Clopidogrel |
Cerebral Infarction | Gangnam Severance Hospital | March 2010 | Phase 4 |
| NCT02616497 | Completed | Drug: Aspirin Drug: Triflusal |
Atherothrombosis | University of Ioannina | September 2015 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA